Reported 3 days ago
Wells Fargo has raised its price target for Health Catalyst, Inc. (NASDAQ:HCAT) to $10 while maintaining a ‘Buy’ rating, highlighting the company's strong growth potential despite its current share price of around $4. The analyst predicts future growth driven by improved bookings and client retention, along with the anticipated performance of its cloud-based services. While short-term legislative concerns exist, they are not expected to affect the company's long-term outlook significantly.
Source: YAHOO